FIELD: medicine.
SUBSTANCE: dermal flap is simulated in laboratory animals on the second day of experiment. Resveratrol is administered ingragastrically in a daily dose of 2.0 mg/kg from the first experimental days every 46 hours.
EFFECT: method is non-toxic, has minimum contraindications, provides the dermal flap survival growth in the reduced circulation, by activating a pre-conditioning process.
1 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR INCREASING SKIN GRAFT SURVIVAL IN REDUCED CIRCULATION ENVIRONMENT WITH USE OF DIHYDROQUERCETIN | 2014 |
|
RU2547786C1 |
METHOD FOR DERMAL FLAP SURVIVAL GROWTH IN REDUCED CIRCULATION WITH L-NORVALINE | 2012 |
|
RU2513619C1 |
METHOD FOR DERMAL FLAP SURVIVAL GROWTH IN REDUCED CIRCULATION WITH MINOXIDIL | 2012 |
|
RU2497201C1 |
METHOD FOR PHARMACOLOGICAL STIMULATION OF PEDICLE SKIN FLAP SURVIVAL WITH NICORANDYL | 2012 |
|
RU2507598C1 |
METHOD OF PHARMACOLOGICAL CORRECTION OF ISCHEMIA OF SKELETAL MUSCLE WITH RESVERATROL | 2012 |
|
RU2518965C1 |
METHOD FOR DERMAL FLAP SURVIVAL GROWTH IN REDUCED CIRCULATION WITH SILDENAFIL | 2012 |
|
RU2498414C1 |
METHOD FOR PHARMACOLOGICAL CORRECTION OF SKELETAL MUSCLE ISCHEMIA WITH L-NORVALINE | 2012 |
|
RU2507596C1 |
METHOD FOR STIMULATING NEOANGIOGENESIS IN ISCHEMIC SKELETAL MUSCLE | 2014 |
|
RU2547692C1 |
METHOD OF PHARMACOLOGICAL CORRECTION OF ISCHEMIC TISSUES SURVIVAL RATE IN REDUCED BLOOD CIRCULATION ENVIRONMENT | 2010 |
|
RU2438190C1 |
METHOD FOR ENDOTHELIAL DYSFUNCTION CORRECTION IN ADMA-LIKE GESTOSIS MODEL IN EXPERIMENT | 2012 |
|
RU2507594C2 |
Authors
Dates
2014-04-10—Published
2012-12-05—Filed